ID   LNCaP C4-2
AC   CVCL_4782
SY   LNCaP-C4-2; LNCaP subline C4-2; C4-2; C42; Sp 2817
DR   ATCC; CRL-3314
DR   BTO; BTO:0005672
DR   cancercelllines; CVCL_4782
DR   ChEMBL-Cells; CHEMBL4295439
DR   ChEMBL-Targets; CHEMBL4296460
DR   Cosmic; 1330914
DR   GEO; GSM3145694
DR   PubChem_Cell_line; CVCL_4782
DR   Wikidata; Q54902814
RX   PubMed=8169003;
RX   PubMed=15162376;
RX   PubMed=26499105;
RX   PubMed=35502546;
WW   https://en.wikipedia.org/wiki/LNCaP
WW   https://web.archive.org/web/20150602153438/http://capcelllines.ca:80/details.asp?id=52
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/c/cell-lines-detail-464.html
CC   Population: Caucasian.
CC   Characteristics: Exhibits androgen-independent growth associated with skeletal metastasis, produces metastases when injected either subcutaneously or orthotopically in intact or castrated mice.
CC   Doubling time: 28.96 hours (GrayJW panel).
CC   Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (PubMed=26499105).
CC   Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
ST   Source(s): PubMed=26499105
ST   Amelogenin: X,Y
ST   CSF1PO: 9,10,11,12
ST   D13S317: 10,11,12
ST   D16S539: 10,11
ST   D5S818: 11,12
ST   D7S820: 9.1,9.3,10.3
ST   TH01: 9
ST   TPOX: 8,9
ST   vWA: 16,17,18
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4783 ! LNCaP C4
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 27
//
RX   PubMed=8169003; DOI=10.1002/ijc.2910570319;
RA   Wu H.-C., Hsieh J.-T., Gleave M.E., Brown N.M., Pathak S.,
RA   Chung L.W.K.;
RT   "Derivation of androgen-independent human LNCaP prostatic cancer cell
RT   sublines: role of bone stromal cells.";
RL   Int. J. Cancer 57:406-412(1994).
//
RX   PubMed=15162376; DOI=10.1002/pros.20031;
RA   Liu A.Y., Brubaker K.D., Goo Y.A., Quinn J.E., Kral S., Sorensen C.M.,
RA   Vessella R.L., Belldegrun A.S., Hood L.E.;
RT   "Lineage relationship between LNCaP and LNCaP-derived prostate cancer
RT   cell lines.";
RL   Prostate 60:98-108(2004).
//
RX   PubMed=26499105; DOI=10.1002/pros.23115;
RA   Castanares M.A., Copeland B.T., Chowdhury W.H., Liu M.M.,
RA   Rodriguez R., Pomper M.G., Lupold S.E., Foss C.A.;
RT   "Characterization of a novel metastatic prostate cancer cell line of
RT   LNCaP origin.";
RL   Prostate 76:215-225(2016).
//
RX   PubMed=35502546; DOI=10.1158/0008-5472.CAN-22-1065;
RA   Abate-Shen C., Nunes de Almeida F.;
RT   "Establishment of the LNCaP cell line -- the dawn of an era for
RT   prostate cancer research.";
RL   Cancer Res. 82:1689-1691(2022).
//